Oral Proteins & Peptides Companies

The global oral proteins and peptides market is projected to grow from USD 8.85 billion in 2025 to USD 24.00 billion by 2030, at a CAGR of 22.1%. This growth is driven by the increasing prevalence of chronic diseases, such as diabetes and central nervous system (CNS) disorders, which often require long-term pharmacological intervention. Advancements in oral protein therapeutics and oral peptide drug delivery systems have also enhanced the bioavailability and stability of these medications. A significant factor contributing to market expansion is the preference of patients for oral medications, as they are typically easier to use and offer better compliance compared to injectable options. Additionally, the growing number of indications for oral macromolecule drugs, particularly in the areas of metabolic disorders, autoimmune conditions, and oncology, further enhances the market potential.

The oral protein-based biopharmaceuticals market is experiencing strong growth but faces several challenges. These include high drug development costs and stringent regulatory approval processes. Additionally, the low bioavailability of oral large-molecule drugs, along with issues such as enzymatic degradation, poor solubility, and the need for frequent dosing, has somewhat limited their adoption.

To know about the assumptions considered for the study download the pdf brochure

However, technological advancements help to overcome these obstacles. For example, Evonik’s EUDRACAP colon technology, which uses EUDRAGIT coatings, allows for targeted drug release in the ileocolonic region. This improves the therapeutic effectiveness of oral peptide pharmaceuticals. Such innovations are particularly important for treating autoimmune diseases, gastrointestinal conditions, and metabolic disorders, where precise drug localization is crucial for achieving optimal outcomes.

Leading industry players invest strategically in next-generation oral biologics to speed up commercialization. For example, in February 2025, Oramed Pharmaceuticals announced the spin-off of its Protein Oral Delivery (POD) technology into a new joint venture called OraTech Pharmaceuticals Inc., in collaboration with Hefei Tianhui Biotech (HTIT). This partnership aims to accelerate the development and commercialization of ORMD-0801 oral insulin and other POD-based oral drug delivery technologies for diabetes and chronic diseases. These initiatives reflect the broader industry trend of improving oral peptide and protein-based drug formulations to enhance efficacy, safety, and patient accessibility.

In January 2025, Novo Nordisk collaborated with Valo Health to discover and develop up to 20 new treatments for obesity, type 2 diabetes, and cardiovascular disease. Additionally, in June 2023, AbbVie and Ironwood Pharmaceuticals announced that they received FDA approval for LINZESS to treat functional constipation in patients aged 6 to 17.

Novo Nordisk A/S (Denmark), AbbVie Inc. (USA), and Pfizer Inc. (USA) hold a significant share of the global oral proteins and peptides market, which is highly consolidated.

Novo Nordisk A/S (Denmark)

Novo Nordisk A/S is headquartered in Denmark and is a leading pharmaceutical company globally, particularly in the area of antidiabetic medications. With its extensive product portfolio, wide geographic presence, and well-established global brand, the company has successfully positioned itself as a market leader. Its focused research and manufacturing capabilities, especially regarding insulins and GLP-1 products—such as RYBELSUS—have played a significant role in its success. The company has increased its share of the global GLP-1 therapy market to 55.3% as of the first quarter of 2024, up from 50.8% in 2021. Last year, Novo Nordisk allocated USD 4.7 billion to research & development, which has strengthened its market position, largely due to its development of oral versions of existing drugs like semaglutide, which have significant potential applications.

AbbVie Inc. (US)

AbbVie Inc. holds the second position among US pharmaceutical companies specializing in oral proteins and peptides. The company offers oral peptides such as linaclotide and has focused intensively on other products like atogepant and ubrogepant, positioning itself to capture a significant share of the market. Through its strategic emphasis on gastrointestinal diseases, AbbVie has successfully maintained its competitive edge, notably with linaclotide. Additionally, AbbVie has been proactive in forming strategic partnerships and collaborations to enhance its portfolio of oral proteins and peptides. These partnerships with biotech firms, academic institutions, and contract research organizations (CROs) allow the company to access cutting-edge technologies and innovative delivery methods, further expanding its presence in the market.

Pfizer Inc. (US)

Pfizer Inc. is one of the leading global health companies based in the US. The company entered the oral peptides market with NURTEC ODT, a CGRP receptor antagonist used to treat episodic migraines. Pfizer's pipeline appears robust; one notable drug in development is Danuglipron, an oral GLP-1 receptor agonist currently in Phase II clinical trials. Pfizer also focuses on strategic business acquisitions to strengthen its portfolio. For instance, NURTEC ODT became part of Pfizer's offerings by acquiring Biohaven Pharmaceutical in October 2022.

Market Ranking

The oral proteins and peptides market is highly consolidated, with the top five players holding 90–95% of the total market share. Novo Nordisk is the leading company, primarily due to its product RYBELSUS, which is at the forefront of the market. The demand for GLP-1 analog drugs is increasing, and the convenience of orally administered medications attracts a larger population to oral peptide drugs, particularly for diabetes treatment. Emerging players contribute the remaining 5–10% of the market share. Competition in the market is driven by the growing preference for oral administration and the expanding therapeutic applications of oral proteins and peptides.

Related Reports:

Oral Proteins & Peptides Market by Molecule (Semaglutide, Linaclotide, Calcitonin), Drug Class (GLP-1 Receptor Agonist, GEP, CGRP), Therapeutic Area (Diabetes, Gastroenterology, Genetic Disorder), Formulation (Tablet, Capsule) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com